Stroke Victims To Be Given Psychedelic Drug DMT In First-Ever US Clinical Trials By Elias Marat for Natural Blaze
The hallucinogenic drug DMT (dimethyltriptamine) could provide crucial aid to stroke victims by minimizing the damage inflicted on victims’ brains as they are rushed to the hospital, according to researchers.
Canadian company Algernon Pharmaceuticals has laid out plans to microdose participants in the first clinical trial of its kind in hopes to help stroke victims’ brains recover faster through a “rewiring” process, reports Metro.
A stroke occurs when blood supplies to a part of the brain is drastically reduced or interrupted, starving the vital organ of fresh oxygen and nutrients and setting in motion the death of crucial nerve cells. In some cases, stroke can even lead to death. About 795,000 people suffer from strokes annually in the U.S.
Support Our Site
Now is your chance to support Gospel News Network.
We love helping others and believe that’s one of the reasons we are chosen as Ambassadors of the Kingdom, to serve God’s children. We look to the Greatest Commandment as our Powering force.
However, researchers at Algernon argue that DMT could play a key role in staving off the worst effects of stroke by sparking the growth of new neurons, effectively turbocharging the healing process.
In the first-ever clinical trials of this kind in the U.S., DMT will soon be administered to stroke patients in the back of ambulances. While the doses will be far too small to trigger any sort of hallucinations, scientists are claiming that the microdoses will still be sufficient for conferring benefits.
The Phase 1 trials could begin as soon as next month, if they receive a green light from authorities. It could still take years before the drug receives approval for human use.
Algernon CEO Christopher Moreau is hopeful that the drug will prove its ability to help heal the brains of those who suffer from a stroke.
“Since we’re dealing with stroke patients, we will be using the sub-hallucinogenic dose, which in pre-clinical studies has still shown to improve neuroplasticity,” Moreau explained.
